© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Richard M. Stone, MD, Program Director, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the CALGB 10603 trial, which explored the use of midostaurin as a treatment for patients with FLT3-mutated acute myeloid leukemia.